{"nctId":"NCT03528577","briefTitle":"A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)","startDateStruct":{"date":"2018-09-22","type":"ACTUAL"},"conditions":["Asthma"],"count":128,"armGroups":[{"label":"Test","type":"EXPERIMENTAL","interventionNames":["Drug: Zero-dose","Drug: 90 mcg of PROAIR® HFA","Drug: 180 mcg of 90 mcg of PROAIR® HFA","Drug: 90 mcg of albuterol sulfate inhalation aerosol"]},{"label":"Reference","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zero-dose","Drug: 90 mcg of PROAIR® HFA","Drug: 180 mcg of 90 mcg of PROAIR® HFA","Drug: 90 mcg of albuterol sulfate inhalation aerosol"]},{"label":"Test Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Zero-dose","Drug: 90 mcg of PROAIR® HFA","Drug: 180 mcg of 90 mcg of PROAIR® HFA","Drug: 90 mcg of albuterol sulfate inhalation aerosol"]},{"label":"Reference Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Zero-dose","Drug: 90 mcg of PROAIR® HFA","Drug: 180 mcg of 90 mcg of PROAIR® HFA","Drug: 90 mcg of albuterol sulfate inhalation aerosol"]}],"interventions":[{"name":"Zero-dose","otherNames":[]},{"name":"90 mcg of PROAIR® HFA","otherNames":[]},{"name":"180 mcg of 90 mcg of PROAIR® HFA","otherNames":[]},{"name":"90 mcg of albuterol sulfate inhalation aerosol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men or non-pregnant women 18 to 65 years of age.\n2. Signed informed consent form that meets all criteria of current Food and Drug Administration (FDA) regulations.\n3. Females of childbearing potential must not be pregnant or lactating (as confirmed by a negative urine pregnancy test\n4. Ability to use inhalation aerosol correctly.\n\nExclusion Criteria:\n\n1. Any clinically significant finding on physical exam in the opinion of the Investigator, would compromise subject's safety or data integrity.\n2. Employees of the Investigator or research center or their immediate family members.\n3. Previous participation in this study.\n4. Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacodynamic Endpoint Post-dose PC20","description":"The primary pharmacodynamic endpoint is the post-dose PC20, which is the provocative concentration of methacholine challenge agent required to reduce the forced expiry volume in one second (FEV1) by 20%, following the administration of different doses of albuterol (or placebo) by inhalation.\n\nPrimary analysis group -pharmacodynamic population.","paramType":"MEAN","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":125},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","gastroenteritis","Myalgia","tension headache"]}}}